LANI Phase III Clinical Trials Set For Enrolment 18 November 2008 Biota Holdings announces that the multiple centres involved in the Phase III clinical trail on its LANI CS-8958 are ready to commence treatment.
Delphi Genetics and Eurogentec Biologics Collaborate for Antibiotic Resistance-Gene Free GMP Manufacturing 14 November 2008 Under the agreement Eurogentec will promote Delphi Genetics’ StabyDNA technology for use in GMP manufacturing on an exclusive basis.
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1 12 November 2008 The initial study will evaluate the safety and combined antiviral activity of R7227 and R7128 in treatment-naive patients infected with HCV genotype 1.
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease 11 November 2008 Resverlogix’s first in class drug illustrates early signal of transport of key amyloid marker from brain.
Clinical Trials Commence for Extended Warfarin Sensitivity Test 11 November 2008 The extended warfarin test incorporates additional markers, including the CYP450 4F2 biomarker exclusively-licensed from Marshfield Clinic.
Geron Scientists and Collaborators Demonstrate TAT2 Enhances Antiviral Function of Immune Cells From HIV+ Donors 10 November 2008 Geron Corporation announced the publication of preclinical data on TAT2, a small molecule telomerase activator.
Genzyme and Osiris Partner to Develop and Commercialize First-in-Class Adult Stem Cell Products 10 November 2008 The strategic alliance will focus Prochymal and Chondrogen, two late-stage adult stem cell treatments that hold significant potential to treat a wide range of diseases.
Oncolytics Biotech Investigators Present Interim U.S. REOLYSIN® Phase II Sarcoma Trial Data 07 November 2008 Oncolytics presents the interim results of the trial investigating intravenous REOLYSIN® in patients with bone and soft tissue sarcomas metastatic to the lung.